Literature DB >> 19936640

Gastrointestinal stromal tumors-a morphological and immunohistochemical study.

Sajid Mushtaq1, Nadira Mamoon, Usman Hassan, Muhammad Iqbal, Muhammad Tahir Khadim, Tariq Sarfraz.   

Abstract

PURPOSE: The rationale of this study was to assess the morphological and immunohistochemical characteristics of gastrointestinal stromal tumor (GIST) along with their risk stratification.
METHODS: Record of 36 cases diagnosed as GIST over a period of 2 years (January 2007 to December 2008) was retrieved. Slides were reviewed for histological typing, immunohistochemical staining, and mitotic count. Cases were divided into very low, low, intermediate, and high-risk groups according to the Fletcher method of risk stratification (Table 1; Fletcher et al. (Int J Surg Pathol 10:81-89, 2002)). Mean, median, and mode were calculated for quantitative variables like age, tumor size, and mitotic count by using SPSS version 14. Frequencies and percentages were also calculated for qualitative variables like results of immunohistochemistry, tumor site, and histological subtypes.
RESULTS: Out of 36 patients, 14 patients were male, and 22 were female. A total of 14 (39%) patients had tumor size between 2 and 5 cm, 13 (36%) patients had size between 5 and 10 cm, and 9 (25%) patients had size >10 cm. There was no tumor less than 2 cm in size. Twenty-one patients (58%) had mitoses <5/50 high power fields (HPF) while seven (20%) had mitoses between 5 and 10/50 HPF and eight (22%) >10/50 HPF. Thirty-one (86%) of cases were strongly positive for CD117 while CD34 was positive in 81% of the cases. Most frequent histological type was hypercellular spindle cell type, and most frequent site of presentation was stomach. Seven patients fell into low risk, ten patients intermediate risk, and 19 patients in high risk groups. There were no patients in very low risk group.
CONCLUSION: By using microscopy and immunohistochemical techniques, GISTs can be diagnosed accurately and treated efficiently. Risk stratification and histological subtyping have emerged as efficient tools to predict malignant behavior.

Entities:  

Mesh:

Year:  2009        PMID: 19936640     DOI: 10.1007/s12029-009-9108-5

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  15 in total

1.  Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal.

Authors:  L G Kindblom; H E Remotti; F Aldenborg; J M Meis-Kindblom
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

Review 2.  GIST under imatinib therapy.

Authors:  Raf Sciot; Maria Debiec-Rychter
Journal:  Semin Diagn Pathol       Date:  2006-05       Impact factor: 3.464

Review 3.  Gastrointestinal stromal tumor (GIST) pathogenesis, familial GIST, and animal models.

Authors:  Cristina R Antonescu
Journal:  Semin Diagn Pathol       Date:  2006-05       Impact factor: 3.464

4.  Clinicopathologic study of 275 cases of gastrointestinal stromal tumors: the experience at 3 large medical centers in Mexico.

Authors:  Isabel Alvarado-Cabrero; Gonzálo Vázquez; Francisca I Sierra Santiesteban; Dulce Ma Hernández-Hernández; Angel Zavala Pompa
Journal:  Ann Diagn Pathol       Date:  2007-02       Impact factor: 2.090

5.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

Authors:  S Hirota; K Isozaki; Y Moriyama; K Hashimoto; T Nishida; S Ishiguro; K Kawano; M Hanada; A Kurata; M Takeda; G Muhammad Tunio; Y Matsuzawa; Y Kanakura; Y Shinomura; Y Kitamura
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

6.  Gastrointestinal stromal tumours (GISTs): a clinicopathological and molecular study of 66 cases.

Authors:  M H Eleanor Koay; Yu-Wei Goh; Barry Iacopetta; Fabienne Grieu; Amanda Segal; Gregory F Sterrett; Michael Platten; Dominic V Spagnolo
Journal:  Pathology       Date:  2005-02       Impact factor: 5.306

Review 7.  Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.

Authors:  Markku Miettinen; Jerzy Lasota
Journal:  Arch Pathol Lab Med       Date:  2006-10       Impact factor: 5.534

Review 8.  Diagnosis of gastrointestinal stromal tumors: a consensus approach.

Authors:  Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss
Journal:  Int J Surg Pathol       Date:  2002-04       Impact factor: 1.271

Review 9.  Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics.

Authors:  Markku Miettinen; Jerzy Lasota
Journal:  Pol J Pathol       Date:  2003       Impact factor: 1.072

10.  Gastrointestinal stromal tumors: a demographic, morphologic and immunohistochemical study.

Authors:  F Rauf; Y Bhurgri; S Pervez
Journal:  Indian J Gastroenterol       Date:  2007 Sep-Oct
View more
  2 in total

1.  Co-expression of monocarboxylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low survival in patients with gastrointestinal stromal tumors (GISTs).

Authors:  Antônio Talvane Torres de Oliveira; Céline Pinheiro; Adhemar Longatto-Filho; Maria Jose Brito; Olga Martinho; Delcio Matos; André Lopes Carvalho; Vinícius Lima Vazquez; Thiago Buosi Silva; Cristovam Scapulatempo; Sarhan Sydney Saad; Rui Manuel Reis; Fátima Baltazar
Journal:  J Bioenerg Biomembr       Date:  2012-01-27       Impact factor: 2.945

2.  Clinicopathologic features and prognostic grouping of gastrointestinal stromal tumors (GISTs) in Pakistani patients: an institutional perspective.

Authors:  Atif Ali Hashmi; Mahrukh Faraz; Zareeha Nauman; Muhammad Usman Qureshi; Shumaila Kanwal Hashmi; Hira Fatima Waseem; Muhammad Muzzammil Edhi; Naveen Faridi; Amir Khan
Journal:  BMC Res Notes       Date:  2018-07-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.